TScan reports early Phase 1 data showing chimerism gains with TSC-101
Tweet Send to a Friend
TScan Therapeutics (Nasdaq: TCRX) reported initial data from Cohort C of its ALLOHA Phase 1 study evaluating TSC-101 in patients ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
